title: In vitro and in vivo anticancer effects of destruxin B on human colorectal cancer.
abstract: OBJECTIVE
  The study of the anticancer effects of destruxin B (DB) is rare and its anticancer mechanism remains unknown. The aim of this study was to test the in vitro and in vivo anticancer effects of DB, on human HT-29 colorectal cancer (CRC).
  
  
  METHODS
  DB was isolated and characterized by high pressure liquid chromatography, electrospray ionization mass spectrometry and (1)H-nuclear magnetic resonance spectroscopy. (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was used to assess the effects of DB on HT-29 cells in vitro. The anticancer effects of DB were investigated in a murine xenograft model of human colon cancer.
  
  
  RESULTS
  A significant inhibition of cell viability was observed with DB treatment in time- and dose-dependent manners. DB administered subcutaneously daily at 0.6-15 mg/kg was proven to be safe and effective in inhibiting the growth of CRC cells. Expression of Bax, cleaved poly (ADP-ribose) polymerase and active caspase-3 were observed with DB treatment and the increase in tumor volumes of treated groups were significantly (p<0.05) lower than those of the mock-treated group.
  
  
  CONCLUSIONS
  DB has potential as a new therapeutic agent against human CRC.
authors: School of Dentistry, Chung Shang Medical University, Taichung, Taiwan, ROC.
authors: Yi-Pang
authors: YP
authors: Lee
authors: Che-Wei
authors: CW
authors: Wang
authors: Wan-Chun
authors: WC
authors: Liao
authors: Chiung-Ru
authors: CR
authors: Yang
authors: Chi-Tai
authors: CT
authors: Yeh
authors: Chung-Hung
authors: CH
authors: Tsai
authors: Chi-Chiang
authors: CC
authors: Yang
authors: Yew-Min
authors: YM
authors: Tzeng
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D001835:Body Weight / Q000187:drug effects; D053148:Caspase 3 / Q000378:metabolism; D002470:Cell Survival / Q000187:drug effects; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D047630:Depsipeptides / Q000737:chemistry / Q000302:isolation & purification / Q000494:pharmacology*; D005260:Female; D019073:HT29 Cells; D006801:Humans; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D009929:Organ Size / Q000187:drug effects; D011065:Poly(ADP-ribose) Polymerases / Q000096:biosynthesis / Q000378:metabolism; D013154:Spleen / Q000033:anatomy & histology / Q000187:drug effects; D023041:Xenograft Model Antitumor Assays; D051028:bcl-2-Associated X Protein / Q000096:biosynthesis
chemical_list: D000970:Antineoplastic Agents; C494826:BAX protein, human; D047630:Depsipeptides; D051028:bcl-2-Associated X Protein; C040424:destruxin B; D011065:Poly(ADP-ribose) Polymerases; D053148:Caspase 3